BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7691253)

  • 1. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma.
    Pettengell R; Testa NG; Swindell R; Crowther D; Dexter TM
    Blood; 1993 Oct; 82(7):2239-48. PubMed ID: 7691253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
    Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
    J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
    Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
    Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
    Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
    Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
    Moskowitz CH; Stiff P; Gordon MS; McNiece I; Ho AD; Costa JJ; Broun ER; Bayer RA; Wyres M; Hill J; Jelaca-Maxwell K; Nichols CR; Brown SL; Nimer SD; Gabrilove J
    Blood; 1997 May; 89(9):3136-47. PubMed ID: 9129016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.
    Lickliter JD; Begley CG; Boyd AW; Szer J; Grigg AP
    Leuk Lymphoma; 1994 Sep; 15(1-2):91-7. PubMed ID: 7532059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
    Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
    Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas.
    Hansen PB; Johnsen HE; Ralfkiaer E; Jensen L; Gaarsdal E; Hansen NE
    Leuk Lymphoma; 1995 Nov; 19(5-6):453-60. PubMed ID: 8590846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
    Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J
    Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
    Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.
    Bender JG; Lum L; Unverzagt KL; Lee W; Van Epps D; George S; Coon J; Ghalie R; McLeod B; Kaizer H
    Bone Marrow Transplant; 1994 Apr; 13(4):479-85. PubMed ID: 7517260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro expansion of CD34+ cells mobilized with chemotherapy and G-CSF.
    Teofili L; Iovino MS; Di Mario A; Ortu La Barbera E; Pierelli L; Bussa S; Rumi C; Menichella G; Leone G
    Int J Artif Organs; 1993 Dec; 16 Suppl 5():89-95. PubMed ID: 7516922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
    Janowska-Wieczorek A; Marquez LA; Nabholtz JM; Cabuhat ML; Montaño J; Chang H; Rozmus J; Russell JA; Edwards DR; Turner AR
    Blood; 1999 May; 93(10):3379-90. PubMed ID: 10233890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
    Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
    Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells.
    Haas R; Möhle R; Pförsich M; Fruehauf S; Witt B; Goldschmidt H; Hunstein W
    Blood; 1995 Apr; 85(7):1936-43. PubMed ID: 7535595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial.
    Lazarus HM; Andersen J; Chen MG; Variakojis D; Mansour EG; Oette D; Arce CA; Oken MM; Gerson SL
    Blood; 1991 Aug; 78(3):830-7. PubMed ID: 1859894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The capacity of peripheral blood stem cells mobilised with chemotherapy plus G-CSF to repopulate irradiated marrow stroma in vitro is similar to that of bone marrow.
    Demuynck H; Pettengell R; de Campos E; Dexter TM; Testa NG
    Eur J Cancer; 1992; 28(2-3):381-6. PubMed ID: 1375485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation.
    Stewart FM; Temeles D; Lowry P; Thraves T; Grosh WW; Quesenberry PJ
    Blood; 1993 May; 81(9):2283-9. PubMed ID: 8481510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.